You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 102

    ABSTRACT Approximately 700,000 people in the United States are diagnosed with a primary brain tumor. Of these, malignant gliomas (MGs) account for approximately 40% of all intracranial tumors, with an overall survival rate of only ~34%. Surgical resection remains the cornerstone of therapy and the extent of resection correlates with survival. Fluorescence imaging has emerged as an adjunctive techn ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

    SBC: NYTRICX INC            Topic: NHLBI

    Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. I-RED Southeast XLerator Network

    SBC: XLERATEHEALTH, LLC            Topic: 500

    Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities

    SBC: Fetal Life, LLC            Topic: 102

    PROJECT SUMMARY To ensure fetal well-being, obstetricians monitor fetal heartrate (FHR) and uterine contractions on a weekly to bi-weekly basis towards the end of pregnancy and during labor. Such monitoring is performed with an electronic fetal monitor (EFM) to decrease the development of complications while minimizing the need for unnecessary obstetric interventions. This is especially important ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Imaging Bacterial Infections in Vivo: First in Man Studies

    SBC: Microbial Medical, Inc.            Topic: NIAID

    Project Summary/AbstractInfection is the major complication of virtually all medical devices. It is estimated that 2 million patients acquire a nosocomial infection in the US every year and the CDC estimates that the financial impact of these infections exceeds 5 billion dollars annually. At least half of these infections are directly associated with medical devices. Most commonly, the diagnosis o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist

    SBC: VIRTUALLY BETTER INC            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. mHealth for Patient Self-Management of Opioid Use Disorder

    SBC: Biomedical Development Corporation            Topic: NIDA

    PROJECT SUMMARY / ABSTRACTThe opioid crisis is an epidemic with devastating health, social, and economic consequences for the United States. From 1999–2018, almost 450,000 people died from an overdose involving any opioid, including prescription and illicit opioids. Three million US citizens and 16 million individuals worldwide have had or currently suffer from opioid use disorder (OUD). The tot ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Small-molecule therapy for metastatic castration-resistant prostate cancer

    SBC: MetCure Therapeutics LLC            Topic: 102

    Metastatic, castration-resistant prostate cancer (mCRPC) is lethal with no cure. Although current treatments initially prolong survival, patients generally relapse and develop therapeutic resistance, which is a major obstacle in the management of prostate cancer. It is imperative to develop efficacious therapies to treat lethal mCRPC and improve the survivorship of patients. During the Phase I STT ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies

    SBC: MOONLIGHT THERAPEUTICS, INC.            Topic: NIAID

    Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies Food allergies affect 15 million people in the USA and 17 million in Europe. Six million children, roughly 1 in 13, in the USA have at least one food allergy; this equates to at least 1 in every classroom. Currently, there are no approved therapies for food allergies anywhere in the world. Food allergies a ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government